PCV65 PHARMACOECONOMIC ANALYSIS OF 160MG VALSARTAN VERSUS LOSARTAN AND TELMISARTAN IN THE TREATMENT OF SYSTEMIC ARTERIAL HYPERTENSION IN THE MEXICAN HEALTH SECTOR
Nov 1, 2005, 00:00 AM
10.1016/S1098-3015(10)67476-1
https://www.valueinhealthjournal.com/article/S1098-3015(10)67476-1/fulltext
Section Title :
Section Order :
41
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)67476-1&doi=10.1016/S1098-3015(10)67476-1